Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes
© The Author(s) 2020..
Germline variants in tumor suppressor genes (TSGs) can result in RNA mis-splicing and predisposition to cancer. However, identification of variants that impact splicing remains a challenge, contributing to a substantial proportion of patients with suspected hereditary cancer syndromes remaining without a molecular diagnosis. To address this, we used capture RNA-sequencing (RNA-seq) to generate a splicing profile of 18 TSGs (APC, ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, and TP53) in 345 whole-blood samples from healthy donors. We subsequently demonstrated that this approach can detect mis-splicing by comparing splicing profiles from the control dataset to profiles generated from whole blood of individuals previously identified with pathogenic germline splicing variants in these genes. To assess the utility of our TSG splicing profile to prospectively identify pathogenic splicing variants, we performed concurrent capture DNA and RNA-seq in a cohort of 1000 patients with suspected hereditary cancer syndromes. This approach improved the diagnostic yield in this cohort, resulting in a 9.1% relative increase in the detection of pathogenic variants, demonstrating the utility of performing simultaneous DNA and RNA genetic testing in a clinical context.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
NPJ precision oncology - 4(2020) vom: 17., Seite 4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Landrith, Tyler [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer genetics |
|---|
| Anmerkungen: |
Date Revised 28.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41698-020-0109-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307244644 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307244644 | ||
| 003 | DE-627 | ||
| 005 | 20240328233516.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41698-020-0109-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1352.xml |
| 035 | |a (DE-627)NLM307244644 | ||
| 035 | |a (NLM)32133419 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Landrith, Tyler |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2020. | ||
| 520 | |a Germline variants in tumor suppressor genes (TSGs) can result in RNA mis-splicing and predisposition to cancer. However, identification of variants that impact splicing remains a challenge, contributing to a substantial proportion of patients with suspected hereditary cancer syndromes remaining without a molecular diagnosis. To address this, we used capture RNA-sequencing (RNA-seq) to generate a splicing profile of 18 TSGs (APC, ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, and TP53) in 345 whole-blood samples from healthy donors. We subsequently demonstrated that this approach can detect mis-splicing by comparing splicing profiles from the control dataset to profiles generated from whole blood of individuals previously identified with pathogenic germline splicing variants in these genes. To assess the utility of our TSG splicing profile to prospectively identify pathogenic splicing variants, we performed concurrent capture DNA and RNA-seq in a cohort of 1000 patients with suspected hereditary cancer syndromes. This approach improved the diagnostic yield in this cohort, resulting in a 9.1% relative increase in the detection of pathogenic variants, demonstrating the utility of performing simultaneous DNA and RNA genetic testing in a clinical context | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cancer genetics | |
| 650 | 4 | |a Genetic testing | |
| 650 | 4 | |a Next-generation sequencing | |
| 700 | 1 | |a Li, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Cass, Ashley A |e verfasserin |4 aut | |
| 700 | 1 | |a Conner, Blair R |e verfasserin |4 aut | |
| 700 | 1 | |a LaDuca, Holly |e verfasserin |4 aut | |
| 700 | 1 | |a McKenna, Danielle B |e verfasserin |4 aut | |
| 700 | 1 | |a Maxwell, Kara N |e verfasserin |4 aut | |
| 700 | 1 | |a Domchek, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Morman, Nichole A |e verfasserin |4 aut | |
| 700 | 1 | |a Heinlen, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Wham, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Koptiuch, Cathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Vagher, Jennie |e verfasserin |4 aut | |
| 700 | 1 | |a Rivera, Ragene |e verfasserin |4 aut | |
| 700 | 1 | |a Bunnell, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Gayle |e verfasserin |4 aut | |
| 700 | 1 | |a Geurts, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Depas, Morgan M |e verfasserin |4 aut | |
| 700 | 1 | |a Gaonkar, Shraddha |e verfasserin |4 aut | |
| 700 | 1 | |a Pirzadeh-Miller, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Krukenberg, Rebekah |e verfasserin |4 aut | |
| 700 | 1 | |a Seidel, Meredith |e verfasserin |4 aut | |
| 700 | 1 | |a Pilarski, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Farmer, Meagan |e verfasserin |4 aut | |
| 700 | 1 | |a Pyrtel, Khateriaa |e verfasserin |4 aut | |
| 700 | 1 | |a Milliron, Kara |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, John |e verfasserin |4 aut | |
| 700 | 1 | |a Hoodfar, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Nathan, Deepika |e verfasserin |4 aut | |
| 700 | 1 | |a Ganzak, Amanda C |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Sitao |e verfasserin |4 aut | |
| 700 | 1 | |a Vuong, Huy |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Arulmoli, Aarani |e verfasserin |4 aut | |
| 700 | 1 | |a Parra, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Hoang, Lily |e verfasserin |4 aut | |
| 700 | 1 | |a Molparia, Bhuvan |e verfasserin |4 aut | |
| 700 | 1 | |a Fennessy, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Charpentier, Sinead |e verfasserin |4 aut | |
| 700 | 1 | |a Burdette, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Pesaran, Tina |e verfasserin |4 aut | |
| 700 | 1 | |a Profato, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Brandon |e verfasserin |4 aut | |
| 700 | 1 | |a Haynes, Ginger |e verfasserin |4 aut | |
| 700 | 1 | |a Dalton, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Crandall, Joy Rae-Radecki |e verfasserin |4 aut | |
| 700 | 1 | |a Baxter, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Hsiao-Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Tippin-Davis, Brigette |e verfasserin |4 aut | |
| 700 | 1 | |a Elliott, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Chao, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Karam, Rachid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ precision oncology |d 2017 |g 4(2020) vom: 17., Seite 4 |w (DE-627)NLM274781727 |x 2397-768X |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2020 |g day:17 |g pages:4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41698-020-0109-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2020 |b 17 |h 4 | ||